Plant Name: Crinum asiaticum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.112E-12 | 5.750E-09 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.061E-07 | 1.540E-04 | BCHE, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.012E-26 | 6.559E-22 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.176E-06 | 2.494E-03 | ACHE, BCHE |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 4.596E-06 | 5.004E-03 | HPGD, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.281E-06 | 5.475E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 6.176E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.729E-06 | 6.732E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.329E-05 | 9.650E-03 | CYP1A2, MAPK1, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.303E-05 | 9.650E-03 | CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.425E-20 | 2.640E-16 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.929E-19 | 4.861E-15 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.375E-25 | 1.774E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.478E-07 | 2.243E-05 | MMP1; MMP2; MAPK1; MMP9 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.220E-05 | 5.245E-04 | MMP2; MAPK1; MMP9; ESR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.409E-04 | 4.440E-03 | MMP1; MMP2; MAPK1; MMP9; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.528E-04 | 3.286E-03 | MAPK1; NFKB1; ESR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.016E-05 | 2.585E-03 | CYP1A2; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.127E-04 | 2.908E-03 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.152E-04 | 6.695E-03 | MMP2; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.330E-04 | 7.639E-03 | MAPK1; MMP9; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.074E-03 | 1.259E-02 | LMNA; MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.212E-03 | 1.302E-02 | MAPK1; MMP9; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.099E-03 | 2.499E-02 | MMP2; MAPK1; MMP9 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.205E-03 | 2.188E-02 | HPGD; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.084E-03 | 2.499E-02 | MAPK1; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.044E-04 | 1.038E-02 | CYP1A2; CYP3A4 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.111E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.084E-03 | 2.499E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.006E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.484E-03 | 2.618E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.006E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.990E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.006E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.742E-03 | 2.618E-02 | CA2; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.140E-03 | 2.618E-02 | PTPN1; MAPK1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.006E-03 | 2.618E-02 | CYP1A2; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.903E-03 | 3.589E-02 | MAPK1; MMP9; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.353E-03 | 3.162E-02 | MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.675E-03 | 3.194E-02 | MMP2; MAPK1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.276E-03 | 2.618E-02 | MAPK1; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.275E-03 | 2.998E-02 | CYP1A2; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 6.881E-03 | 3.162E-02 | MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.740E-03 | 3.657E-02 | MAPK1; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.124E-02 | 3.816E-02 | ACHE; MAPK1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.029E-02 | 3.688E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.923E-03 | 3.657E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.923E-03 | 3.657E-02 | MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.086E-02 | 3.785E-02 | PTPN1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.263E-02 | 4.005E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.304E-02 | 4.005E-02 | MAPK1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.263E-02 | 4.005E-02 | MMP2; MMP9 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.562E-02 | 4.646E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.304E-02 | 4.005E-02 | MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.585E-02 | 4.646E-02 | MAPK1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.722E-02 | 4.937E-02 | PTPN1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.230E-03 | 3.162E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; TOP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; TOP1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | TOP1; TOP1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MAPK1; MMP9; NFKB1; MMP2; TOP1; ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | TOP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Gastric cancer | C16 | TOP1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MAPK1; MMP9; MMP2; TOP1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TOP1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TOP1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | TOP1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | TOP1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; TOP1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; TOP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TOP1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | TOP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Advanced ovarian cancer | NA | TOP1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | TOP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |